Global Cerebral Atrophy Detected by Routine Imaging: Relationship with Age, Hippocampal Atrophy, and White Matter Hyperintensities
- 5 January 2018
- journal article
- research article
- Published by Wiley in Journal of Neuroimaging
- Vol. 28 (3) , 301-306
Abstract
BACKGROUND AND PURPOSE: Interpreting the clinical significance of moderate‐to‐severe global cerebral atrophy (GCA) is a conundrum for many clinicians, who visually interpret brain imaging studies in routine clinical practice. GCA may be attributed to normal aging, Alzheimer's disease (AD), or cerebrovascular disease (CVD). Understanding the relationships of GCA with aging, AD, and CVD is important for accurate diagnosis and treatment decisions for cognitive complaints.METHODS: To elucidate the relative associations of age, moderate‐to‐severe white matter hyperintensities (WMHs), and moderate‐to‐severe medial temporal lobe atrophy (MTA), with moderate‐to‐severe GCA, we visually rated clinical brain imaging studies of 325 participants from a community based sample. Logistic regression analysis was conducted to assess the relations of GCA with age, WMH, and MTA.RESULTS: The mean age was 76.2 (±9.6) years, 40.6% were male, and the mean educational attainment was 15.1 (±3.7) years. Logistic regression results demonstrated that while a 1‐year increase in age was associated with GCA (OR = 1.04; P = .04), MTA (OR = 3.7; P < .001), and WMH (OR = 8.80; P < .001) were strongly associated with GCA in our study population. Partial correlation analysis showed that the variance of GCA explained by age is less than the variance attributed to MTA and WMH (r = .13, .21, and .43, respectively).CONCLUSIONS: Moderate‐to‐severe GCA is most likely to occur in the presence of AD or CVD and should not be solely attributed to age when evaluating clinical imaging findings in the workup of cognitive complaints. Developing optimal diagnostic and treatment strategies for cognitive decline in the setting of GCA requires an understanding of its risk factors in the aging population.Keywords
Funding Information
- National Institutes of Health (NR014189, P30 AG028383, R01 AG042419, UH2 NS100606)
This publication has 37 references indexed in Scilit:
- Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegenerationThe Lancet Neurology, 2013
- Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scansNeurobiology of Aging, 2010
- One-Year Brain Atrophy Evident in Healthy AgingThe Journal of Neuroscience, 2009
- Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohortBMJ, 2009
- White Matter Lesions and Brain Atrophy: More than Shared Risk Factors? A Systematic ReviewCerebrovascular Diseases, 2009
- Understanding White Matter DiseaseStroke, 2009
- Measuring Cerebral Atrophy and White Matter Hyperintensity Burden to Predict the Rate of Cognitive Decline in Alzheimer DiseaseArchives of Neurology, 2008
- White matter lesion progression, brain atrophy, and cognitive decline: The Austrian stroke prevention studyAnnals of Neurology, 2005
- Impact of White Matter Changes on Clinical Manifestation of Alzheimer’s DiseaseStroke, 2000
- White Matter Hyperintensities on MRI in the Neurologically Nondiseased ElderlyStroke, 1995